Prescription hormone replacement therapy requires a clinician’s involvement in the United States, the UK, and most other regulated countries, but “seeing a doctor” no longer means sitting in a waiting room. Telehealth platforms now connect patients with prescribers entirely online, and a handful of hormone-containing products sit on store shelves without any prescription at all. The practical answer depends on which hormones you need, why you need them, and how much risk you’re willing to accept by skipping the safety checks that medical oversight provides.
Telehealth Has Changed What “Seeing a Doctor” Means
If your real question is whether you can avoid an in-person visit, the answer for many people is yes. Direct-to-consumer telehealth companies have expanded rapidly, offering consultations and prescriptions for hormonal medications through video calls or even asynchronous questionnaires. These services still involve a licensed prescriber reviewing your health history and writing a prescription, so they are not truly doctor-free. But they eliminate geographic barriers, reduce wait times, and let you handle the entire process from your phone or laptop.
For menopausal hormone therapy specifically, several telehealth platforms now specialize in menopause care, pairing patients with clinicians who focus on hormone prescribing. A review in Obstetrics & Gynecology noted that these direct-to-consumer companies have the potential to improve access to prescription-only hormonal medications for women who might otherwise struggle to find a knowledgeable provider nearby.1Obstetrics & Gynecology. Telemedicine Companies Providing Prescription-Only Medications: Pros, Cons, and Proposed Guidelines The convenience is real, though how thoroughly these platforms evaluate your individual risk factors varies from company to company.
For gender-affirming hormone therapy, telehealth has been even more transformative. Transgender and gender-diverse people have historically faced a shortage of knowledgeable providers, lengthy gatekeeping assessments, and insurance roadblocks. A scoping review in Transgender Health found that telemedicine emerged as a clear facilitator for both accessing and providing gender-affirming care, helping to bridge the gap left by a limited pool of competent in-person clinicians.2Transgender Health. Barriers and Facilitators to Accessing and Providing Gender Affirming Hormone Therapy: A Scoping Review Informed-consent clinics, many of which now operate via telehealth, allow patients to begin hormones after discussing risks and benefits without requiring a psychiatric evaluation first.
What You Can Actually Buy Without a Prescription
A small number of hormone-containing products are legally sold over the counter in the United States, though none of them are the standard estrogen or testosterone formulations that doctors prescribe for menopause or gender-affirming care.
Over-the-counter progesterone creams are the most notable example. Sold in pharmacies and online for nominally “cosmetic” purposes, these topical creams contain bioidentical progesterone and deliver meaningful amounts of the hormone through the skin. One pharmacokinetic study found no significant difference in total progesterone exposure between an OTC cream and an FDA-approved oral progesterone capsule when doses were compared proportionally.3PubMed. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product That finding raises a legitimate concern: these creams are pharmacologically active products being sold without the safety guardrails applied to prescription drugs.
Whether OTC progesterone creams actually protect the uterine lining the way prescription progesterone does remains controversial. The creams produce very low levels of progesterone in blood serum, even though levels in saliva and capillary blood run high. A limited number of studies have reported a protective effect on the endometrium, but the evidence is far from settled.4PubMed. Treatment of postmenopausal women with topical progesterone creams and gels: are they effective? Using these creams as a substitute for prescribed progesterone in a formal HRT regimen is a gamble, and no major medical society recommends it.
Phytoestrogens are the other category you’ll encounter. These are plant-derived compounds found in soy, red clover, and various supplements marketed to menopausal women. They weakly mimic estrogen in the body, and some women report feeling better on them. The research, however, is underwhelming. A Cochrane review concluded that there is no conclusive evidence phytoestrogen supplements effectively reduce the frequency or severity of hot flashes and night sweats, though high doses of genistein (an isoflavone concentrated from soy) may offer some relief and warrant further study.5Cochrane Database of Systematic Reviews. Dietary phytoestrogens for vasomotor menopausal symptoms A separate meta-analysis did find a modest reduction in hot flash frequency with phytoestrogens compared to placebo, but the overall symptom burden measured by a standard index showed no significant improvement.6PubMed Central. Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review If your symptoms are mild, phytoestrogens might take the edge off. If they’re disrupting your sleep and daily life, these supplements are unlikely to be a real substitute for prescription HRT.
The Reality of Self-Medication
Some people bypass the medical system entirely and obtain hormones on their own, whether from online pharmacies, overseas sources, or informal networks. This is most documented in transgender communities, where barriers to care have historically been steep. A study of transgender women in San Francisco found that inconsistent access to healthcare leads many to buy hormones from unlicensed sources and transition without medical supervision.7PubMed. Non-Prescribed Hormone Use and Barriers to Care for Transgender Women in San Francisco Research in Ontario, Canada, confirmed that self-prescribing of hormones was prevalent among transgender people who had experienced difficulty accessing care through conventional channels.2Transgender Health. Barriers and Facilitators to Accessing and Providing Gender Affirming Hormone Therapy: A Scoping Review
Self-medication isn’t limited to gender-affirming care. Research on testosterone self-medication found that people turned to unregulated sources because doctors were reluctant or unable to prescribe, but also because of price, ease of access, and a perception that clinicians lacked expertise about testosterone use.8PubMed Central. Testing the boundaries: Self-medicated testosterone replacement and why it is practised The motivations are understandable, but the risks are genuine. Supervised hormone therapy is considered safe when based on evidence-based protocols with appropriate follow-up. Unsupervised use, depending on the person’s existing health conditions, can introduce serious side effects.9PubMed Central. Nonprescribed Hormone Use and Self-Performed Surgeries: “Do-It-Yourself” Transitions in Transgender Communities in Ontario, Canada
Product quality is another concern with unregulated sources. A study examining hormone products purchased online (in this case, somatropin, a growth hormone) found that every sample obtained from internet sources had significantly lower active ingredient concentration than labeled.10PubMed. Availability and quality of illegitimate somatropin products obtained from the Internet While that study looked at growth hormone rather than estrogen or testosterone specifically, it illustrates a broader problem with buying pharmaceuticals from unlicensed vendors: you cannot be sure what’s in the vial or how potent it is.
Why the Type of Estrogen and How You Take It Matters
One of the strongest reasons medical oversight helps is that hormone therapy isn’t one-size-fits-all, and the route of administration changes the risk profile substantially. Estrogen taken as a pill passes through the liver before entering general circulation, and that “first pass” triggers changes in clotting factors. A randomized trial found that oral estrogen significantly increased markers of blood clotting activation compared to no treatment, while transdermal (patch or gel) estrogen had no substantial effect on the clotting system at all.11PubMed. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
This isn’t a small technical distinction. A systematic review and meta-analysis found that oral estrogen carried roughly 60% higher risk of a first venous blood clot and about double the risk of deep vein thrombosis compared to transdermal estrogen.12PubMed. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis For someone with risk factors for blood clots, like a higher body mass index, a personal or family history of clotting events, or certain genetic variants, that difference is clinically meaningful. A scoping review confirmed that transdermal estrogen did not increase clot risk even in women with prior clotting episodes, elevated BMI, or prothrombotic genetic variants.13PubMed. Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review
A person self-prescribing estrogen might default to the cheapest or most available oral formulation without knowing their personal clot risk. A clinician, on the other hand, can steer someone toward transdermal delivery when the risk profile calls for it. This is one of those cases where the medical involvement isn’t about gatekeeping but about genuinely matching the right product to the right patient.
The Progesterone Question for Anyone With a Uterus
If you have a uterus and are taking estrogen, progesterone isn’t optional. Estrogen stimulates the growth of the uterine lining, and without progesterone to oppose that growth, the lining can thicken abnormally over time. Progesterone is a key hormone that counterbalances estrogen-driven growth in the endometrium; insufficient progesterone can lead to the development of endometrial hyperplasia and ultimately cancer.14PubMed Central. Role of progesterone in endometrial cancer A Cochrane review confirmed that unopposed estrogen is associated with increased risk of endometrial hyperplasia at all doses and across therapy durations of one to three years, and recommended that postmenopausal women with an intact uterus receive both estrogen and progestogen.15Cochrane Database of Systematic Reviews. Hormone therapy for postmenopausal women with an intact uterus
This is a straightforward safety issue that self-prescribers sometimes get wrong. Someone buying estrogen online without understanding the need for progesterone could be exposing themselves to a cancer risk that proper prescribing would eliminate. And as discussed earlier, the over-the-counter progesterone creams that are easily available have not been conclusively shown to protect the endometrium the way prescription formulations do.
Blood Monitoring and Gender-Affirming Testosterone
For people using testosterone as part of gender-affirming care, one specific risk that demands monitoring is erythrocytosis, an increase in red blood cell concentration. Current guidelines recommend checking blood counts routinely during the first year, sometimes as often as every three months. A study tracking the first 20 months of testosterone therapy found that about one in eight patients developed a mildly elevated hematocrit, though the severe form was rare, occurring in less than 1% of cases.16PubMed Central. Erythrocytosis in Gender-Affirming Care With Testosterone That same study suggested the screening schedule could be relaxed since severe cases were so uncommon, but a baseline understanding of your blood values still matters before starting testosterone.
Beyond red blood cell counts, gender-affirming hormone therapy shifts several lab values in ways that affect how other health conditions are monitored. Reference ranges for kidney function markers, heart biomarkers, and hemoglobin all differ between typical male and female ranges, and clinicians need to interpret these values according to the patient’s affirmed gender once hormones have been established.17Clinical Chemistry. Laboratory Monitoring in Transgender and Gender-Diverse Individuals Someone self-administering testosterone without any medical contact could miss early warning signs that a simple blood draw would catch.
How the Women’s Health Initiative Made HRT Harder to Get
If you’ve tried to get menopausal HRT and felt like doctors were reluctant to prescribe it, there’s a historical reason for that. In 2002, the Women’s Health Initiative trial was stopped early after finding that the combination of oral conjugated estrogen and medroxyprogesterone acetate carried more health risks than benefits in healthy postmenopausal women. The fallout was enormous. Physician interviews revealed that the study fundamentally changed clinical practice: doctors reported they no longer prescribed HRT for disease prevention and were more likely to suggest women stop taking it.18PubMed Central. How the Women’s Health Initiative (WHI) influenced physicians’ practice and attitudes
The numbers tell the story. HRT initiation rates dropped from about 9% before the WHI to under 3% afterward, and continuation rates fell from 84% to 62%.19PubMed Central. Menopausal Hormone Therapy Trends Before Versus After 2002: Impact of the Women’s Health Initiative Study Results Prescribing rates have remained low in the two decades since.20PubMed Central. Menopause hormone therapy prescribing in ambulatory care visits among midlife and older U.S. women from 2018 to 2019
The irony is that the WHI findings, while important, were more nuanced than the panic that followed. The specific formulation studied was oral conjugated equine estrogen plus a synthetic progestin, given to women whose average age was 63. Many menopause specialists now argue that younger symptomatic women using modern formulations, particularly transdermal estrogen with micronized progesterone, face a very different risk calculus. But the cultural memory of the WHI scare persists, and many primary care physicians remain cautious about prescribing HRT. That caution is part of what drives patients toward telehealth menopause clinics and, in some cases, toward self-treatment.
Pharmacists and Expanding Access Models
Some proposals aim to make hormones more accessible by expanding who can prescribe or manage them. Pharmacists, for example, are increasingly seen as potential partners in hormone therapy management. Various guidelines already exist to help pharmacists assist with gender-affirming hormone therapy, including resources from the World Professional Association for Transgender Health, the Endocrine Society, and the University of California, San Francisco.21Journal of the American Pharmacists Association. Gender-affirming care: A pharmacist’s guide to inclusive and patient-centered care In some jurisdictions, pharmacists already have prescriptive authority for certain medications, and extending that to hormone therapy is an active area of policy discussion.
These models recognize something important: the bottleneck in HRT access often isn’t the medication itself but the prescriber. When there aren’t enough doctors trained in menopause medicine or gender-affirming care, patients either wait months for appointments, travel long distances, or look for workarounds. Expanding the pool of qualified prescribers through telehealth, pharmacist involvement, and nurse practitioner authority could reduce the pressure that pushes people toward unsupervised self-medication in the first place. None of these models eliminate clinical oversight; they redistribute it to make it less of a barrier while keeping the safety guardrails in place.